A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study is being done to establish "normal' values for a new blood test and urine test approach to cancer screening. Patients undergo blood and urine sample collection on study. Patients' medical records are reviewed.
Eligibility criteria
Qualifiers
10,000 patients without a known internal (non-cutaneous) cancer or a history of an internal cancer
To balance age, rough recruitment goals will be set for the following subsets: 18-39 years, 40-49 years , 50-59 years , 60-69 years , 70-79 years , and >= 80 years
To balance sex, roughly half of the participants recruited within each age subset will be women
Roughly half of all participants will have had a colonoscopy or colon x-ray within the past 5 years, or Cologuard® test in the last 3 years which were negative for cancer and precancerous lesions
Disqualifiers
Patients has a past or current diagnosis of invasive cancer (this does not include basal cell or squamous cell skin cancers)
Patient has had a solid organ transplant
Inability to give informed consent
Patient has transurethral instrumentation (cystoscopy, placement of urinary catheter) within the 7 days prior to sample collection
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
10,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov